Source link : https://www.newshealth.biz/health-news/vorasidenib-for-certain-idh-mutant-gliomas-is-it-worth-it/
The emergence of vorasidenib, the first targeted therapy for certain gliomas with IDH mutations, has ignited a wave of excitement in both patient and physician spaces. After years with limited treatment options, experts hailed vorasidenib “a promising breakthrough,” “a paradigm shift,” a “new hope,” and “probably the most important advance in the treatment of low-grade […]
Author : News Health
Publish date : 2024-12-02 09:06:22
Copyright for syndicated content belongs to the linked Source.